We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Gilead Sciences (GILD - Free Report) will report quarterly earnings of $2.17 per share in its upcoming release, pointing to a year-over-year decline of 12.2%. It is anticipated that revenues will amount to $7.81 billion, exhibiting an increase of 0.6% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 1.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Gilead metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Product Sales- HIV- Odefsey- Total' should come in at $202.57 million. The estimate suggests a change of -26.9% year over year.
Analysts expect 'Total product sales- Total' to come in at $7.75 billion. The estimate suggests a change of +5.6% year over year.
Based on the collective assessment of analysts, 'Revenues- Royalty contract and other revenues' should arrive at $62.02 million. The estimate indicates a year-over-year change of -85.4%.
Analysts' assessment points toward 'Product Sales- Liver Disease- Vemlidy- Total' reaching $252.48 million. The estimate points to a change of -9.8% from the year-ago quarter.
The average prediction of analysts places 'Product Sales- HIV- Genvoya- U.S.' at $249.96 million. The estimate suggests a change of -22.6% year over year.
It is projected by analysts that the 'Total product sales- U.S.' will reach $5.74 billion. The estimate indicates a change of +8.9% from the prior-year quarter.
The consensus estimate for 'Product Sales- HIV- Odefsey- U.S.' stands at $162.41 million. The estimate indicates a change of -21.2% from the prior-year quarter.
The consensus among analysts is that 'Product Sales- Liver Disease- Vemlidy- U.S.' will reach $118.92 million. The estimate indicates a change of -12.6% from the prior-year quarter.
Analysts predict that the 'Product Sales- Oncology- Cell Therapy- Yescarta- U.S.' will reach $103.23 million. The estimate suggests a change of -16.1% year over year.
The combined assessment of analysts suggests that 'Product Sales- HIV- Biktarvy- U.S.' will likely reach $3.12 billion. The estimate points to a change of +6.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Product Sales- HIV- Symtuza-Revenue share- U.S.' of $97.34 million. The estimate indicates a year-over-year change of +2.5%.
Analysts forecast 'Product Sales- Veklury- U.S.' to reach $34.23 million. The estimate suggests a change of -75.6% year over year.
Over the past month, Gilead shares have recorded returns of +3.4% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #3 (Hold), GILD will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Gilead Sciences (GILD - Free Report) will report quarterly earnings of $2.17 per share in its upcoming release, pointing to a year-over-year decline of 12.2%. It is anticipated that revenues will amount to $7.81 billion, exhibiting an increase of 0.6% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 1.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Gilead metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Product Sales- HIV- Odefsey- Total' should come in at $202.57 million. The estimate suggests a change of -26.9% year over year.
Analysts expect 'Total product sales- Total' to come in at $7.75 billion. The estimate suggests a change of +5.6% year over year.
Based on the collective assessment of analysts, 'Revenues- Royalty contract and other revenues' should arrive at $62.02 million. The estimate indicates a year-over-year change of -85.4%.
Analysts' assessment points toward 'Product Sales- Liver Disease- Vemlidy- Total' reaching $252.48 million. The estimate points to a change of -9.8% from the year-ago quarter.
The average prediction of analysts places 'Product Sales- HIV- Genvoya- U.S.' at $249.96 million. The estimate suggests a change of -22.6% year over year.
It is projected by analysts that the 'Total product sales- U.S.' will reach $5.74 billion. The estimate indicates a change of +8.9% from the prior-year quarter.
The consensus estimate for 'Product Sales- HIV- Odefsey- U.S.' stands at $162.41 million. The estimate indicates a change of -21.2% from the prior-year quarter.
The consensus among analysts is that 'Product Sales- Liver Disease- Vemlidy- U.S.' will reach $118.92 million. The estimate indicates a change of -12.6% from the prior-year quarter.
Analysts predict that the 'Product Sales- Oncology- Cell Therapy- Yescarta- U.S.' will reach $103.23 million. The estimate suggests a change of -16.1% year over year.
The combined assessment of analysts suggests that 'Product Sales- HIV- Biktarvy- U.S.' will likely reach $3.12 billion. The estimate points to a change of +6.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Product Sales- HIV- Symtuza-Revenue share- U.S.' of $97.34 million. The estimate indicates a year-over-year change of +2.5%.
Analysts forecast 'Product Sales- Veklury- U.S.' to reach $34.23 million. The estimate suggests a change of -75.6% year over year.
View all Key Company Metrics for Gilead here>>>Over the past month, Gilead shares have recorded returns of +3.4% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #3 (Hold), GILD will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .